loading

Kymera Therapeutics Inc Borsa (KYMR) Ultime notizie

pulisher
May 22, 2025

Stifel Nicolaus Begins Coverage on Kymera Therapeutics (NASDAQ:KYMR) - Defense World

May 22, 2025
pulisher
May 22, 2025

Deutsche Bank AG Has $2.91 Million Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR) - Defense World

May 22, 2025
pulisher
May 20, 2025

Kymera Therapeutics (KYMR) Receives 'Buy' Rating from Stifel with $55 Price Target | KYMR Stock News - GuruFocus

May 20, 2025
pulisher
May 20, 2025

Kymera Therapeutics (KYMR) Gains Buy Rating from Stifel with Promising Outlook | KYMR Stock News - GuruFocus

May 20, 2025
pulisher
May 19, 2025

Kymera’s KT-621 shows promise in preclinical asthma study - Investing.com Australia

May 19, 2025
pulisher
May 19, 2025

Kymera Therapeutics (KYMR) Showcases Promising Preclinical Data - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-621, a - GuruFocus

May 19, 2025
pulisher
May 19, 2025

Kymera’s KT-621 shows promise in preclinical asthma study By Investing.com - Investing.com India

May 19, 2025
pulisher
May 19, 2025

Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the American Thoracic Society International Conference - The Manila Times

May 19, 2025
pulisher
May 19, 2025

Kymera Therapeutics presents preclinical data for KT-621 - TipRanks

May 19, 2025
pulisher
May 19, 2025

Breakthrough: New Oral Asthma Drug Shows Superior Results to Dupilumab in Latest Clinical Data - Stock Titan

May 19, 2025
pulisher
May 14, 2025

Transcript : Kymera Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 03 - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Kymera at BofA Conference: Strategic FDA and Manufacturing Insights By Investing.com - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Kymera at BofA Conference: Strategic FDA and Manufacturing Insights - Investing.com

May 14, 2025
pulisher
May 14, 2025

Kymera TherapeuticsIntriguing Degradation Thesis, But A Bit Powder Puff (NASDAQ:KYMR) - Seeking Alpha

May 14, 2025
pulisher
May 13, 2025

Kymera Therapeutics (KYMR) Target Price Adjusted by UBS | KYMR S - GuruFocus

May 13, 2025
pulisher
May 13, 2025

UBS Adjusts Price Target on Kymera Therapeutics to $70 From $72, Maintains Buy Rating - marketscreener.com

May 13, 2025
pulisher
May 13, 2025

Kymera Therapeutics (KYMR) Target Price Revised by UBS | KYMR St - GuruFocus

May 13, 2025
pulisher
May 13, 2025

Analysts Are Betting On Kymera Therapeutics, Inc. (NASDAQ:KYMR) With A Big Upgrade This Week - simplywall.st

May 13, 2025
pulisher
May 13, 2025

When the Price of (KYMR) Talks, People Listen - news.stocktradersdaily.com

May 13, 2025
pulisher
May 12, 2025

The Analyst Verdict: Kymera Therapeutics In The Eyes Of 4 Experts - Benzinga

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics (KYMR) Receives Reaffirmed 'Buy' Rating from - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics (KYMR) Stock Rating Maintained, Price Target - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics (KYMR) Faces Price Target Reduction Amid Str - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Truist maintains Kymera Therapeutics stock buy rating and $35 target By Investing.com - Investing.com UK

May 12, 2025
pulisher
May 12, 2025

Kymera unveils new oral IRF5 degrader for immuno-inflammatory diseases - BioWorld MedTech

May 12, 2025
pulisher
May 12, 2025

B. Riley Adjusts Kymera Therapeutics Price Target to $38 From $41, Maintains Neutral Rating - marketscreener.com

May 12, 2025
pulisher
May 12, 2025

BofA Adjusts Price Target for Kymera Therapeutics (KYMR) | KYMR Stock News - GuruFocus

May 12, 2025
pulisher
May 12, 2025

Kymera Therapeutics: Promising Pipeline and Strategic Decisions Justify Buy Rating - TipRanks

May 12, 2025
pulisher
May 10, 2025

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Q1 2025 Earnings Call Transcript - Insider Monkey

May 10, 2025
pulisher
May 10, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and ... - Yahoo Finance

May 10, 2025
pulisher
May 10, 2025

Kymera advances oral drug for autoimmune diseases - Investing.com

May 10, 2025
pulisher
May 10, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings Call Highlights: Strategic Advances and Financial Resilience - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Kymera Therapeutics (NASDAQ:KYMR) Shares Gap Up on Strong Earnings - Defense World

May 10, 2025
pulisher
May 10, 2025

Decoding Kymera Therapeutics Inc (KYMR): A Strategic SWOT Insigh - GuruFocus

May 10, 2025
pulisher
May 10, 2025

Kymera advances oral drug for autoimmune diseases By Investing.com - Investing.com India

May 10, 2025
pulisher
May 10, 2025

Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 - Investing.com

May 10, 2025
pulisher
May 09, 2025

Kymera (KYMR) Financial Update: Strong Cash Position Supports Future Developments | KYMR Stock News - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Reports Strong Pipeline Progress - TipRanks

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics (KYMR) Launches Innovative Oral Immunology P - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars t - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Announces First Quarter 2025 Financial Resul - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics (KYMR) Surpasses Revenue Estimates with Stro - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Expands Industry Leading Immunology Pipeline - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics’ Earnings Call: Resilience and Strategic Growth - TipRanks

May 09, 2025
pulisher
May 09, 2025

Earnings call transcript: Kymera Therapeutics beats EPS forecast in Q1 2025 By Investing.com - Investing.com South Africa

May 09, 2025
pulisher
May 09, 2025

Truist maintains Buy on Kymera stock, reiterates $53 target By Investing.com - Investing.com Canada

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Q1 2025 Earnings Call Transcript - MarketBeat

May 09, 2025
pulisher
May 09, 2025

Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging - Zacks Investment Research

May 09, 2025
pulisher
May 09, 2025

Kymera (KYMR) Financial Update: Strong Cash Position Supports Fu - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Q1 Loss Widens, Collaboration Revenue Rises - marketscreener.com

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics Inc (KYMR) Q1 2025 Earnings: Revenue Soars to $22.1M, Beating Estimates; Net Loss Widens - GuruFocus

May 09, 2025
pulisher
May 09, 2025

Kymera Therapeutics (KYMR) Surpasses Revenue Estimates with Strong Q1 Performance | KYMR Stock News - GuruFocus

May 09, 2025
$1.15
price down icon 17.27%
$31.32
price down icon 3.63%
$587.61
price up icon 1.06%
$289.96
price up icon 0.33%
$4.25
price up icon 0.48%
$75.06
price up icon 3.26%
Capitalizzazione:     |  Volume (24 ore):